Company / Operating Income
Jazz Pharmaceuticals Operating Income History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income
-$430.2M
FY2025
5-year range
-$430.2M / $716.6M
FY2021-FY2025
Trend
-160.0%
vs FY2024
Sector context
#183 of 204
Health Care
What the data says
Among 204 Health Care companies, Jazz Pharmaceuticals is in the bottom 10% for operating income. Operating Income has fluctuated over the past 10 years, ranging from -$430M in FY2025 to $717M in FY2024.
Based on SEC 10-K filings.
-$430M in FY2025.
Declined from $579M to -$430M over the past 2 years.
Health Care sector context is included.
Operating Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 10% in Health CareTop 90% of 204This company -$430.2M Sector average $107.8M
▼
-499.3% below sector average
Key checks
Key Insights
- In FY2025, operating income decreased 160.0% year-over-year.
- Ranks #183 out of 204 companies in the Health Care sector.
- Peak operating income was recorded in FY2024.
Company context
Key Data Points
- Altman Z-Score 0.66 (distress zone, below 1.8 threshold)
- Negative profit margin: -8.9%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$430.2M | -160.0% |
| FY2024 | $716.6M | +23.9% |
| FY2023 | $578.6M | +53.0% |
| FY2022 | $378.1M | -29.0% |
| FY2021 | $532.4M | -13.4% |
| FY2020 | $614.8M | +16.3% |
| FY2019 | $528.8M | -10.6% |
| FY2018 | $591.7M | +11.9% |
| FY2017 | $528.8M | +170.4% |
| FY2016 | $195.6M | -61.5% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026